Relmada Therapeutics Inc Income Statement

RLMD $34.67 0.2 0.5%

20/04/21

Speculative, Mid Cap, Sucker Stock

Market Cap £413.1m

Enterprise Value £329.3m

Revenue £n/a

Quality

Value

Momentum

StockRank™

To unlock Relmada Therapeutics Inc's income statement please upgrade your membership.

	2016	2017	2018	2019	2019	2020
Period End:	2016-06-30	2017-06-30	2018-06-30	2019-06-30	2019-12-31	2020-12-31
Period Length:	12M	12M	12M	12M	6M	12M
Currency:	USD	USD	USD	USD	USD	USD

Total Revenue


Selling/General/Administrative Expenses, Total
Research & Development
Unusual Expense (Income)

Total Operating Expense
Operating Profit/Income

Interest Income (Expense), Net Non-Operating
Gain (Loss) on Sale of Assets
Total Non Operating Interest Expense
Other, Net
Income Before Tax
Income Tax - Total
Income After Tax

Net Income Before Extra. Items
Total Extraordinary Items
Net Income

Income Available to Common Excl. Extra. Items
Income Available to Common Incl. Extra. Items
Diluted Net Income
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Incl. Extraordinary Items
Diluted EPS Excluding Extraordinary Items

Normalized Income Before Taxes
Normalized Income After Taxes
Normalized Inome Avail to Common Stock
Diluted Normalized EPS

Dividends per Share - Common Stock Primary Issue

Unlock Stockopedia Premium for free!

See what it can do for your stockpicking and portfolio at no expense.